Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

To read more Press Release articles, click here.